A phase II trial evaluating the efficacy of high‐dose Radioiodinated Tositumomab ( Anti‐CD20 ) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high‐risk relapsed or refractory non‐hodgkin lymphoma-Reference-Cited by-同舟云学术

A phase II trial evaluating the efficacy of high‐dose Radioiodinated Tositumomab ( Anti‐CD20 ) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high‐risk relapsed or refractory non‐hodgkin lymphoma

Published:2020-04-22 Issue:7 Volume:95 Page:775-783
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Chow Victor A.¹²^ORCID,Rajendran Joseph G.³,Fisher Darrell R.⁴,Appelbaum Frederick R.¹²,Cassaday Ryan D.²⁵,Martin Paul S.¹,Holmberg Leona A.¹²,Gooley Theodore A.⁶,Stevenson Philip A.⁶,Pagel John M.⁷,Green Damian J.¹²,Press Oliver W.¹²,Gopal Ajay K.¹²^ORCID

Affiliation:

1. Division of Medical Oncology, Department of MedicineUniversity of Washington Seattle WA USA

2. Clinical Research DivisionFred Hutchinson Cancer Research Center Seattle WA USA

3. Department of RadiologyUniversity of Washington Seattle WA USA

4. Versant Medical Physics and Radiation Safety Richland WA USA

5. Division of Hematology, Department of MedicineUniversity of Washington Seattle WA USA

6. Public Health DivisionFred Hutchinson Cancer Research Center Seattle WA USA

7. Center for Blood Disorders and Stem Cell TransplantationSwedish Cancer Institute Seattle WA USA

Funder

National Institutes of Health

Publisher

Wiley